{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:22Z","timestamp":1781650822367,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirogabalin and trimethoprim-sulfamethoxazole (TMP\/SMX) are frequently used as supportive purpose during and\/or after chemotherapy. Mirogabalin is used to treat neuropathic pain, whereas TMP\/SMX is used to prevent pneumocystis pneumonia (PCP) in patients who are immunocompromised. The interaction between mirogabalin and TMP\/SMX has not been reported. Here, we report a case of akathisia that developed after concurrent administration of mirogabalin and TMP\/SMX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 69-year-old male patient who experienced akathisia twice. The patient was diagnosed with diffuse large B-cell lymphoma and treated with the polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola-R-CHP) regimen. On the fifth day of treatment, TMP\/SMX at a dosage of 80\u00a0mg\/400\u00a0mg once daily was initiated to prevent PCP. On day 20 of treatment, mirogabalin treatment was initiated for neuropathic pain probably due to polatuzumab vedotin. Akathisia first manifested on the day following the initiation of mirogabalin treatment, occurring 30\u00a0min after the administration of TMP\/SMX. The patient experienced pruritus and dyspnea. Discontinuation of TMP\/SMX resulted in the amelioration of symptoms. Akathisia occurred a second time, when TMP\/SMX was resumed, resulting in itching of the upper body, symptoms of restlessness, and an inability to remain still. Based on these symptoms, the patient was diagnosed with akathisia. Following discontinuation of both TMP\/SMX and mirogabalin, the symptoms improved. These episodes suggested the possibility that the concurrent use of mirogabalin and TMP\/SMX caused akathisia. Blood concentration measurements obtained at symptom onset did not reveal a significant increase in mirogabalin levels, suggesting that the adverse event was unlikely to be explained solely by an increase in mirogabalin concentration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Concurrent use of mirogabalin and TMP\/SMX may have been associated with the development of akathisia in the present case. Based on the potential for similar interactions, caution should be exercised when administering this drug to patients undergoing chemotherapy. To the best of our knowledge, this is the first case report describing akathisia associated with the concomitant use of mirogabalin and TMP\/SMX, highlighting the need for careful monitoring of patients receiving both drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00578-y","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:19:10Z","timestamp":1777025950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Akathisia induced by concurrent use of mirogabalin and sulfamethoxazole-trimethoprim: a case report"],"prefix":"10.1186","volume":"12","author":[{"given":"Takashi","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitaka","family":"Suetsugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Terazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"578_CR1","doi-asserted-by":"publisher","unstructured":"Aaron V, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37(12):3253\u201361. https:\/\/doi.org\/10.2337\/dc14-1044.","DOI":"10.2337\/dc14-1044"},{"key":"578_CR2","doi-asserted-by":"publisher","unstructured":"Seretny M, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461\u201370. https:\/\/doi.org\/10.1016\/j.pain.2014.09.020.","DOI":"10.1016\/j.pain.2014.09.020"},{"issue":"24","key":"578_CR3","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","volume":"23","author":"SE Jones","year":"2005","unstructured":"Jones SE, et al. Randomized phase\u2162 study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23(24):5542\u201351. https:\/\/doi.org\/10.1200\/JCO.2005.02.027.","journal-title":"J Clin Oncol"},{"issue":"3","key":"578_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00001813-199506000-00003","volume":"6","author":"DS Alberts","year":"1995","unstructured":"Alberts DS, et al. Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs. 1995;6(3):369\u201383. https:\/\/doi.org\/10.1097\/00001813-199506000-00003.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"578_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1186\/s12885-023-11560-4","volume":"23","author":"S Misawa","year":"2023","unstructured":"Misawa S, et al. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study). BMC Cancer. 2023;23(1):1098. https:\/\/doi.org\/10.1186\/s12885-023-11560-4.","journal-title":"BMC Cancer"},{"issue":"1","key":"578_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1186\/s12885-021-09069-9","volume":"21","author":"M Sugimoto","year":"2021","unstructured":"Sugimoto M, et al. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021;21(1):1319. https:\/\/doi.org\/10.1186\/s12885-021-09069-9.","journal-title":"BMC Cancer"},{"issue":"9","key":"578_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.10052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052\u20139. https:\/\/doi.org\/10.4065\/82.9.10052.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"578_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s1083-8791(00)70050-4","volume":"6","author":"MJ Vasconcelles","year":"2000","unstructured":"Vasconcelles MJ. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transpl. 2000;6(1):35\u201343. https:\/\/doi.org\/10.1016\/s1083-8791(00)70050-4.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"578_CR9","doi-asserted-by":"publisher","first-page":"e0122171","DOI":"10.1371\/journal.pone.0122171","volume":"10","author":"X Jiang","year":"2015","unstructured":"Jiang X, et al. Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PLoS ONE. 2015;10(4):e0122171. https:\/\/doi.org\/10.1371\/journal.pone.0122171. eCollection 2015.","journal-title":"PLoS ONE"},{"issue":"4","key":"578_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351\u201363. doi: 10. 1056\/NEJMoa2115304. Epub 2021 Dec 14.","journal-title":"N Engl J Med"},{"issue":"16","key":"578_CR11","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood.2022017734","volume":"141","author":"Y Song","year":"2023","unstructured":"Song Y, et al. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood. 2023;141(16):1971\u201381. https:\/\/doi.org\/10.1182\/blood.2022017734.","journal-title":"Blood"},{"issue":"1","key":"578_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1192\/bjp.179.1.4","volume":"179","author":"M Poyurovsky","year":"2001","unstructured":"Poyurovsky M, et al. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry. 2001;179(1):4\u20138. https:\/\/doi.org\/10.1192\/bjp.179.1.4.","journal-title":"Br J Psychiatry"},{"issue":"14","key":"578_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s1092852900026201","volume":"12","author":"N Iqbal","year":"2007","unstructured":"Iqbal N, et al. Akathisia: problem of history or concern of today. CNS Spectr. 2007;12(14):1\u201313. https:\/\/doi.org\/10.1017\/s1092852900026201.","journal-title":"CNS Spectr"},{"issue":"1","key":"578_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jcph.974","volume":"58","author":"M Kato","year":"2018","unstructured":"Kato M, et al. Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects with Varying Degrees of Renal Impairment. J Clin Pharmacol. 2018;58(1):57\u201363. https:\/\/doi.org\/10.1002\/jcph.974.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"578_CR15","doi-asserted-by":"publisher","first-page":"e00418","DOI":"10.1002\/prp2.418","volume":"6","author":"K Brown","year":"2018","unstructured":"Brown K, et al. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies. Pharmacol Res Prespect. 2018;6(5):e00418. https:\/\/doi.org\/10.1002\/prp2.418. eCollection 2018 Oct.","journal-title":"Pharmacol Res Prespect"},{"issue":"4","key":"578_CR16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s12325-022-02424-7","volume":"40","author":"Y Li","year":"2023","unstructured":"Li Y, et al. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study. Adv Ther. 2023;40(4):1628\u201343. https:\/\/doi.org\/10.1007\/s12325-022-02424-7.","journal-title":"Adv Ther"},{"issue":"6","key":"578_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1055\/s-2006-951608","volume":"39","author":"M Deuschle","year":"2006","unstructured":"Deuschle M, et al. Dyskinesia during treatment with duloxetine. Pharmacopsychiatry. 2006;39(6):237\u20138. https:\/\/doi.org\/10.1055\/s-2006-951608.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"578_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3344\/kjp.2021.34.1.4","volume":"34","author":"J Kim","year":"2021","unstructured":"Kim J, et al. Mirogabalin: could it be the next generation gabapentin or pregabalin? Korean J Pain. 2021;34(1):4\u201318. https:\/\/doi.org\/10.3344\/kjp.2021.34.1.4.","journal-title":"Korean J Pain"},{"issue":"4","key":"578_CR19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1345\/aph.1R699","volume":"47","author":"E Dag","year":"2013","unstructured":"Dag E, et al. Pregabalin-induced akathisia. Ann Pharmacother. 2013;47(4):592\u20133. https:\/\/doi.org\/10.1345\/aph.1R699.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"578_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4103\/bc.bc_57_19","volume":"6","author":"JP Rissardo","year":"2020","unstructured":"Rissardo JP, et al. Pregabalin-associated movement disorders: A literature review. Brain Circ. 2020;6(2):96\u2013106. https:\/\/doi.org\/10.4103\/bc.bc_57_19.","journal-title":"Brain Circ"},{"issue":"10","key":"578_CR21","first-page":"596","volume":"59","author":"P Br\u00e4unig","year":"1988","unstructured":"21), Br\u00e4unig P, et al. Cortisone-induced psychoses. Nervenarzt. 1988;59(10):596\u2013602.","journal-title":"Nervenarzt"},{"issue":"2","key":"578_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol ther"},{"issue":"3","key":"578_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jac\/4.3.203","volume":"4","author":"RW Barling","year":"1978","unstructured":"Barling RW, et al. The penetration of antibiotics into cerebrospinal fluid and brain tissue. J Antimicrob Chemother. 1978;4(3):203\u201327. https:\/\/doi.org\/10.1093\/jac\/4.3.203.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"578_CR24","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1093\/jac\/dks283","volume":"67","author":"K Lee","year":"2012","unstructured":"Lee K, et al. Acute psychosis related to use of trimethoprim\/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study. J Antimicrob Chemother. 2012;67(11):2749\u201354. https:\/\/doi.org\/10.1093\/jac\/dks283.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"578_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.mehy.2010.07.021","volume":"75","author":"S Mehdi","year":"2010","unstructured":"Mehdi S. Antibiotic-induced psychosis: a link to D-alanine? Med Hypotheses. 2010;75(6):676\u20137. https:\/\/doi.org\/10.1016\/j.mehy.2010.07.021.","journal-title":"Med Hypotheses"},{"issue":"1","key":"578_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13256-016-0883-x","volume":"10","author":"J Ninan","year":"2016","unstructured":"Ninan J, et al. Imipenem-cilastatin-induced psychosis: a case report. J Med Case Rep. 2016;10(1):107. https:\/\/doi.org\/10.1186\/s13256-016-0883-x.","journal-title":"J Med Case Rep"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00578-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00578-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00578-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:39:55Z","timestamp":1781649595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00578-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00578-y","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee for Epidemiological Research at the Sakuragaoka Campus of Kagoshima University (Approval No 250085 Case Report), and written informed consent for participation was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the study findings and any accompanying images or data was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}